Unleashing the power of ATTOBODY® technology to develop new medicines
ATTOBODIES are biparatopic biologics that utilize a proprietary spatial positioning technology. Each ATTOBODY binds to two different epitopes on the target molecule, creating a two-handed hold. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, which drives strong potency in biologic activity. Depending on desired application, the affinity can be tuned. ATTOBODY binder arms are small, with the potential to bind target difficult-to-access epitopes, and their biparatopic binding can functionalizes epitopes that individually are biologically inactive. ATTOBODIES are modular, nimble in multispecifics, and offer tunable half-life from hours to weeks with potential for quarterly dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform significantly accelerates development and offers a high degree of diversity in lead candidates, expanding target biology coverage and derisking development.
Unleashing the power of ATTOBODY® technology to develop new medicines
ATTOBODIES are biparatopic biologics that utilize a proprietary spatial positioning technology. Each ATTOBODY binds to two different epitopes on the target molecule, creating a two-handed hold. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, which drives strong potency in biologic activity. Depending on desired application, the affinity can be tuned. ATTOBODY binder arms are small, with the potential to bind target difficult-to-access epitopes, and their biparatopic binding can functionalizes epitopes that individually are biologically inactive. ATTOBODIES are modular, nimble in multispecifics, and offer tunable half-life from hours to weeks with potential for quarterly dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform significantly accelerates development and offers a high degree of diversity in lead candidates, expanding target biology coverage and derisking development.
ATTOBODY®
ATTOBODIES are composed of two binder arms connected through proprietary spatial positioning technology. This technology orients the arms in an optimal configuration to drive desired target engagement.
Currently, our ATTOBODIES utilize VHHs as their binder arms. The VHH format is a well-understood framework that is clinically and commercially validated, naturally derived, and easily obtained. In the future, we envision bringing additional binder options to our platform to further broaden our potential at targeting diseases that remain unaddressed by current treatments.
ATTOBODIES are a flexible modality that can be used in their native form, as well as easily built out as bi- and multimers, fused to Fc-domains to modulate effector functions or extending half-life, or conjugated to various payloads.
ATTOBODY®
ATTOBODIES are composed of two binder arms connected through proprietary spatial positioning technology. This technology orients the arms in an optimal configuration to drive desired target engagement.
Currently, our ATTOBODIES utilize VHHs as their binder arms. The VHH format is a well-understood framework that is clinically and commercially validated, naturally derived, and easily obtained. In the future, we envision bringing additional binder options to our platform to further broaden our potential at targeting diseases that remain unaddressed by current treatments.
ATTOBODIES are a flexible modality that can be used in their native form, as well as easily built out as bi- and multimers, fused to Fc-domains to modulate effector functions or extending half-life, or conjugated to various payloads.
The ATTOBODY advantage
Best-in-class potency
Biparatopic binding offers picomolar affinity with glue-like binding for best-in-class potency. The affinity can be tuned for optimal pharmacodynamics.
Unlock new biology
ATTOBODIES co-opt biologically inactive single epitopes, expanding target druggability potential. Together with the high-throughput, evolution-driven nature of the ATTOBODY discovery platform, this contributes to our ability to generate first-in-class and best-in-class medicines.
Breakthrough efficacy through nimble multispecifics
ATTOBODIES are highly modular. Discovered as biparatopic building blocks, they can be combined into multispecifics in a number of formats.
Tunable half-life
ATTOBODIES are easily fused to a variety of half-life extension fragments, offering a range of half-life options from hours to weeks, with potential for quarterly dosing in patients.
Unparalleled speed of development
Due to its high-throughput nature, the availability of glue-like molecules directly from discovery, and modularity, the ATTOBODY platform can deliver development candidates within a year or less from immunization.
Best-in-class potency
Biparatopic binding offers picomolar affinity with glue-like binding for best-in-class potency. The affinity can be tuned for optimal pharmacodynamics.
Unlock new biology
ATTOBODIES co-opt biologically inactive single epitopes, expanding target druggability potential. Together with the high-throughput, evolution-driven nature of the ATTOBODY discovery platform, this contributes to our ability to generate first-in-class and best-in-class medicines.
Breakthrough efficacy through nimble multispecifics
ATTOBODIES are highly modular. Discovered as biparatopic building blocks, they can be combined into multispecifics in a number of formats.
Tunable half-life
ATTOBODIES are easily fused to a variety of half-life extension fragments, offering a range of half-life options from hours to weeks, with potential for quarterly dosing in patients.
Unparalleled speed of development
Due to its high-throughput nature, the availability of glue-like molecules directly from discovery, and modularity, the ATTOBODY platform can deliver development candidates within a year or less from immunization.
